Tercica Announces the Appointment of Richard A. King as Chief Operating Officer

BRISBANE, Calif.
Feb 28, 2007

Tercica, Inc. (Nasdaq:TRCA) today announced that Richard A. King has been appointed as Chief Operating Officer. Mr. King, 42, previously served as Executive Vice President, Commercial Operations of Kos Pharmaceuticals, Inc. from 2002 to 2006, where he was responsible for sales, marketing, managed care, sales operations and customer service functions. Under his commercial leadership, Kos realized revenue growth from $90 million in 2001 to approximately $750 million in 2005. Kos attained profitability in 2003, and by 2006, when the company was acquired by Abbott Laboratories, Mr. King had approximately 1,000 professional personnel reporting to him.

Prior to his employment at Kos, from 2000 to 2002 Mr. King was Senior Vice President of Commercial Operations at Solvay Pharmaceuticals, and from 1992 to 2000, held various marketing positions at SmithKline Beecham Pharmaceuticals. A native of the United Kingdom, Mr. King began his career in the pharmaceutical industry at Lederle Laboratories, Ltd. He holds a Bachelor of Science degree in Chemical Engineering from the University of Surrey, and an MBA from Manchester Business School.

"Richard's appointment reflects both the addition of an extraordinarily accomplished commercial executive to the Tercica management team, and the maturation of Tercica to a multi-product company with an emerging leadership position in the endocrine marketplace," commented Dr. John Scarlett, President and Chief Executive Officer of Tercica.

About Tercica
Tercica is a biopharmaceutical company committed to improving endocrine health by partnering with the endocrine community to develop and commercialize new therapeutics for short stature and other metabolic disorders. For further information on Tercica, please visit www.tercica.com.